Pfizer Earning Billions Treating Covid Vax-Induced Turbo Cancers

Pfizer is boasting that the pharmaceutical giant is now raking in billions of dollars in profits from treating the turbo cancer epidemic that was triggered by the company’s Covid mRNA vaccines.

According to company CEO Albert Bourla, Pfizer is cashing in from new “blockbuster” cancer drugs.

Bourla, a World Economic Forum (WEF) “agenda contributor,” is gloating that treating turbo cancers is “our new Covid.”

Speaking with Fox Business about how Pfizer plans to score big on the new turbo cancer market, Bourla announced that the deadly epidemic is translating into big profits for Pfizer investors.

Since profits from the company’s mRNA (modRNA) COVID jabs are drying up, Bourla is ready to unleash new chemical drugs to reinvigorate the profit streams.

The “pandemic” brought record revenue to Pfizer, which generated an astounding $157 billion overall from not just its “vaccine” but also Paxlovid, an oral antiviral medication.

In 2023, however, sales were down by more than half at only around $71 billion.

Since the end of 2022, Pfizer’s share price has likewise fallen by 42 percent due to a rapid decline in demand for all things COVID-related.

Pfizer responded with a major cost-cutting campaign that included laying off hundreds of people at its United Kingdom and United States facilities.

Of course, Bourla and the other executives at Pfizer were never planning to take a pay cut.

Conveniently, the company is now cashing in on the turbo cancer epidemic caused by the Covid mRNA injections.

As deadly cancers continue to spread rapidly among the general public, Big Pharma elites are enjoying the spoils.

“Oncology: it is our new COVID,” Bourla said excitedly, grinning from ear to ear while giving all the credit to himself and his friends.

“We did what we did with COVID.

“We are very proud to have saved the world but it is behind us now.

“We want to do [it] once more and I think oncology is our best chance to do it.”

Just before the turn of the new year, Pfizer completed a $43 billion acquisition of Seagen (formerly known as Seattle Genetics), a biotechnology company that specializes in the development of monoclonal antibody-based drugs, also known as antibody-drug conjugates or ADCs.

“They are designed to kill tumor cells while leaving healthy tissues relatively unaffected,” is how RT described ADCs.

Adcetris is the drug that landed Seagen on the map, its uses being for the treatment of lymphoma and Hodgkin’s lymphoma.

The drug costs around $11.91 for a single 50-milligram dose.

Seagen also has another drug in its portfolio called Padcev which Bourla described as showing “phenomenal performance.”

Padcev is used to treat bladder cancer, and sales of it have increased by 164 percent since Pfizer acquired Seagen.

The price of Padcev is much more expensive than Adcetris, costing an astounding $4,446 for a single 30-milligram dose.

“That demonstrates how well we’ve invested the money,” Bourla said proudly, adding that in the future the Pfizer drug “will have a significant impact on cancer patients.”

Pfizer’s shift into oncology was announced in late 2023 with Bourla indicating that this is sure to bring in the cash seeing as how fearful people are about getting cancer.

“Nothing scares people all over the world more than cancer because it affects everyone,” he explained.

“I hope we will be successful in our mission.

“I am optimistic that in the next 10 years, we will see significant advancement.”

By 2030, Pfizer plans to have at least eight blockbuster cancer drugs on the market, as well as double the number of patients being treated with them – as of 2023, Pfizer is treating 2.3 million cancer patients.